Answer
VIMOVO is indicated for symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in adults at risk of NSAID-associated gastric and/or duodenal ulcers when lower doses of naproxen or other NSAIDs are not considered sufficient.
Sources for this answer
- VIMOVO 500 mg/20 mg modified-release tabletsGrunenthal Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 19Document updated
Sources checked